- Home
- GMAB vs EVRG Comparison
GMAB vs EVRG Comparison
Compare GMAB & EVRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- EVRG
- Stock Information
- Founded
- GMAB 1999
- EVRG 2017
- Country
- GMAB Denmark
- EVRG United States
- Employees
- GMAB N/A
- EVRG N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- EVRG Power Generation
- Sector
- GMAB Health Care
- EVRG Utilities
- Exchange
- GMAB Nasdaq
- EVRG Nasdaq
- Market Cap
- GMAB 17.4B
- EVRG 17.9B
- IPO Year
- GMAB N/A
- EVRG N/A
- Fundamental
- Price
- GMAB $28.66
- EVRG $75.59
- Analyst Decision
- GMAB Strong Buy
- EVRG Strong Buy
- Analyst Count
- GMAB 7
- EVRG 10
- Target Price
- GMAB $41.50
- EVRG $77.35
- AVG Volume (30 Days)
- GMAB 2.6M
- EVRG 2.2M
- Earning Date
- GMAB 11-06-2025
- EVRG 11-06-2025
- Dividend Yield
- GMAB N/A
- EVRG 3.68%
- EPS Growth
- GMAB 132.41
- EVRG N/A
- EPS
- GMAB 25.10
- EVRG 3.66
- Revenue
- GMAB $3,845,670,022.00
- EVRG $5,878,800,000.00
- Revenue This Year
- GMAB $24.92
- EVRG $5.19
- Revenue Next Year
- GMAB $15.97
- EVRG $3.76
- P/E Ratio
- GMAB $11.14
- EVRG $20.67
- Revenue Growth
- GMAB 29.57
- EVRG 1.75
- 52 Week Low
- GMAB $17.24
- EVRG $59.67
- 52 Week High
- GMAB $33.65
- EVRG $79.32
- Technical
- Relative Strength Index (RSI)
- GMAB 40.06
- EVRG 41.64
- Support Level
- GMAB $28.08
- EVRG $74.76
- Resistance Level
- GMAB $29.35
- EVRG $77.36
- Average True Range (ATR)
- GMAB 0.65
- EVRG 1.20
- MACD
- GMAB -0.27
- EVRG -0.44
- Stochastic Oscillator
- GMAB 25.93
- EVRG 16.10
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About EVRG Evergy Inc.
Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission Co. The utility has a combined rate base of approximately $20 billion, about half in Kansas and the rest split between Missouri and federal jurisdiction. Evergy is one of the largest wind energy suppliers in the US.